Learning Objectives
Upon completion of this education program the participant should be able to:

• Describe and apply the clinical manifestations and the diagnostic criteria as outlined by the Second International Workshop on Waldenström’s Macroglobulinemia Consensus Panel;
• Recognize and distinguish the differences between symptomatic and asymptomatic (smoldering) Waldenström’s macroglobulinemia (WM), other lymphoproliferative diseases with associated IgM monoclonal gammopathies, and IgM monoclonal gammopathy of undetermined significance (MGUS);
• Describe and discuss the prognostic factors and treatment criteria for WM;
• Review the available treatment options for WM and discuss novel therapeutic agents being evaluated for the disease.

Target Audience
This learning activity is intended for medical oncologists, hematologists, stem cell transplant physicians, and other interested healthcare professionals who treat and manage myeloma and related diseases in the hematology/oncology and transplant patient settings.